Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Light Chain (AL) Amyloidosis Clear all
Recruiting Phase 1 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Duarte, California • Irvine, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

NCT00458822
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 1 Interventional

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

NCT03000660
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax, Dexamethasone
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

NCT00520767
View directory record Official record
Conditions
Primary Systemic Amyloidosis, Light Chain Deposition Disease
Interventions
bortezomib, dexamethasone, melphalan, microarray analysis, flow cytometry, laboratory biomarker analysis, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
7
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

NCT02994784
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
Propylene Glycol-Free Melphalan Hydrochloride
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 2 Interventional

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

NCT00075621
View directory record Official record
Conditions
Multiple Myeloma
Interventions
filgrastim, melphalan, autologous peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Jul 24, 2026, 2:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

NCT06569147
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Elranatamab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
View directory record Official record
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction

NCT00547365
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Human immune globulin intravenous (IGIV)
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Knoxville, Tennessee • Powell, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 1 Interventional

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

NCT01728259
View directory record Official record
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
pomalidomide, bortezomib, dexamethasone, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 2 Interventional Results available

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

NCT00075608
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, autologous stem cell transplantation, stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 3 Interventional Results available

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

NCT02489500
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Bortezomib, Melphalan, Neupogen, Stem Cell Collection, Stem cell infusion
Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT01758042
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia
Interventions
Haploidentical Bone Marrow/Kidney
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 3 Interventional

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

NCT05184088
View directory record Official record
Conditions
Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Interventions
[18F]florbetaben
Drug
Lead sponsor
Lantheus Germany GmbH
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Kansas City, Kansas • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

NCT02909036
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
Device · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Radioimmunoimaging of AL Amyloidosis

NCT00807872
View directory record Official record
Conditions
Primary Amyloidosis
Interventions
124I-labeled monoclonal antibody Mu 11-1F4
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

NCT02245867
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 1Phase 2 Interventional

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

NCT03678259
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
124I-p5+14 Injection
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 24, 2026, 2:34 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

NCT04316442
View directory record Official record
Conditions
Light Chain (AL) Amyloidosis
Interventions
STI-6129
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264
View directory record Official record
Conditions
Primary Amyloidosis
Interventions
NEOD001
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jul 24, 2026, 2:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

Radioimmunoimaging of Light Chain (AL) Amyloidosis

NCT01815086
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
Biological
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jul 24, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

NCT01078454
View directory record Official record
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
melphalan, dexamethasone, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
209
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Aurora, Colorado + 140 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Jul 24, 2026, 2:34 AM EDT
Terminated Phase 1 Interventional

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

NCT01807286
View directory record Official record
Conditions
Myeloma
Interventions
Pomalidomide, Melphalan, Dexamethasone, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Jul 24, 2026, 2:34 AM EDT